{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:03:06Z","timestamp":1794265386531,"version":"4.9.0"},"reference-count":201,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"DOI":"10.1186\/s10020-026-01491-8","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:47:13Z","timestamp":1778057233000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Decoding GPCR signaling reprogramming in cancer: molecular mechanisms and therapeutic implications"],"prefix":"10.1186","volume":"32","author":[{"given":"Shorouk","family":"Aldeyarbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"El-Deyarbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf A.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelal S.","family":"Adi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salahdein","family":"Aburuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"1491_CR1","doi-asserted-by":"publisher","unstructured":"Adams R, Moser B, Karagiannis SN, Lacy KE. Chemokine pathways in cutaneous melanoma: their modulation by cancer and exploitation by the clinician. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13225625.","DOI":"10.3390\/cancers13225625"},{"key":"1491_CR2","doi-asserted-by":"publisher","unstructured":"Ahmadzadehfar H, Essler M. It is time to move forward into the era of theranostics. EJNMMI Res. 2018. https:\/\/doi.org\/10.1186\/s13550-018-0364-x.","DOI":"10.1186\/s13550-018-0364-x"},{"key":"1491_CR3","doi-asserted-by":"publisher","unstructured":"Ahmed MB, Alghamdi AAA, Islam SU, Lee JS, Lee YS. cAMP signaling in cancer: a PKA-CREB and EPAC-centric approach. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11132020.","DOI":"10.3390\/cells11132020"},{"key":"1491_CR4","doi-asserted-by":"publisher","unstructured":"Al Hadidi S, Szabo A, Mohan Lal B, Bag A, Zhen S, Ogunsesan Y, et al. Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2025;15. https:\/\/doi.org\/10.1038\/s41408-025-01386-7","DOI":"10.1038\/s41408-025-01386-7"},{"key":"1491_CR5","doi-asserted-by":"publisher","unstructured":"Arakaki AKS, Pan WA, Lin H, Trejo JA. The \u03b1-arrestin ARRDC3 suppresses breast carcinoma invasion by regulating G protein-coupled receptor lysosomal sorting and signaling. Journal of Biological Chemistry. 2018;293. https:\/\/doi.org\/10.1074\/jbc.RA117.001516","DOI":"10.1074\/jbc.RA117.001516"},{"key":"1491_CR6","doi-asserted-by":"publisher","unstructured":"Arang N, Gutkind JS. G Protein-Coupled receptors and heterotrimeric G proteins as cancer drivers. FEBS Lett. 2020. https:\/\/doi.org\/10.1002\/1873-3468.14017.","DOI":"10.1002\/1873-3468.14017"},{"key":"1491_CR7","doi-asserted-by":"publisher","unstructured":"Armstrong AJ, Geva R, Chung HC, Lemech C, Miller WH, Hansen AR, et al. CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial. Invest New Drugs. 2024. https:\/\/doi.org\/10.1007\/s10637-023-01410-2.","DOI":"10.1007\/s10637-023-01410-2"},{"key":"1491_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56010015","volume":"56","author":"B Arneth","year":"2019","unstructured":"Arneth B. Tumor microenvironment. Medicina (b Aires). 2019;56:15. https:\/\/doi.org\/10.3390\/medicina56010015.","journal-title":"Medicina (b Aires)"},{"key":"1491_CR9","doi-asserted-by":"publisher","unstructured":"Arora P, Cuevas BD, Russo A, Johnson GL, Trejo J. Persistent transactivation of EGFR and ErbB2\/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene. 2008;27. https:\/\/doi.org\/10.1038\/onc.2008.84","DOI":"10.1038\/onc.2008.84"},{"key":"1491_CR10","doi-asserted-by":"publisher","unstructured":"Arora P, Ricks TK, Trejo JA. Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. J Cell Sci. 2007;120. https:\/\/doi.org\/10.1242\/jcs.03409","DOI":"10.1242\/jcs.03409"},{"key":"1491_CR11","doi-asserted-by":"publisher","unstructured":"Ashraf B, McKenzie J, Armstrong AJ. Beyond PSMA: theranostic cell surface targets in metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2025. https:\/\/doi.org\/10.1038\/s41391-025-01037-9.","DOI":"10.1038\/s41391-025-01037-9"},{"key":"1491_CR12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ccell.2015.02.002","volume":"27","author":"SX Atwood","year":"2015","unstructured":"Atwood SX, Sarin KY, Whitson RJ, Li JR, Kim G, Rezaee M, et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell Elsevier. 2015;27:342\u201353.","journal-title":"Cancer Cell Elsevier"},{"key":"1491_CR13","doi-asserted-by":"publisher","unstructured":"Aust G, Zheng L, Quaas M. To detach, migrate, adhere, and metastasize: CD97\/ADGRE5 in cancer. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11091538.","DOI":"10.3390\/cells11091538"},{"key":"1491_CR14","doi-asserted-by":"publisher","unstructured":"Bagnato A, Rosan\u00f2 L. Endothelin-1 receptor drives invadopodia: Exploiting how \u03b2-arrestin-1 guides the way. Small GTPases. 2018. https:\/\/doi.org\/10.1080\/21541248.2016.1235526.","DOI":"10.1080\/21541248.2016.1235526"},{"key":"1491_CR15","doi-asserted-by":"publisher","unstructured":"Balijepalli P, Sitton CC, Meier KE. Lysophosphatidic acid signaling in cancer cells: what makes lpa so special? Cells. 2021. https:\/\/doi.org\/10.3390\/cells10082059.","DOI":"10.3390\/cells10082059"},{"key":"1491_CR16","doi-asserted-by":"publisher","unstructured":"Bessudo A, Haseeb AM, Reeves JA, Zhu X, Wong L, Giranda V, et al. Safety and efficacy of Vicriviroc (MK-7690) in combination with Pembrolizumab in patients with advanced or metastatic microsatellite stable colorectal cancer. Clin Colorectal Cancer. 2024. https:\/\/doi.org\/10.1016\/j.clcc.2024.05.003.","DOI":"10.1016\/j.clcc.2024.05.003"},{"key":"1491_CR17","doi-asserted-by":"publisher","unstructured":"Bian D, Mahanivong C, Yu J, Frisch SM, Pan ZK, Ye RD, et al. The G12\/13-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration. Oncogene. 2006. https:\/\/doi.org\/10.1038\/sj.onc.1209261.","DOI":"10.1038\/sj.onc.1209261"},{"key":"1491_CR18","doi-asserted-by":"publisher","unstructured":"Bouyahya A, Mechchate H, Oumeslakht L, Zeouk I, Aboulaghras S, Balahbib A, et al. The role of epigenetic modifications in human cancers and the use of natural compounds as epidrugs: mechanistic pathways and pharmacodynamic actions. Biomolecules. 2022. https:\/\/doi.org\/10.3390\/biom12030367.","DOI":"10.3390\/biom12030367"},{"key":"1491_CR19","doi-asserted-by":"publisher","unstructured":"Brown JR, DuBois RN. COX-2: A molecular target for colorectal cancer prevention. J Clin Oncol 2005;23. https:\/\/doi.org\/10.1200\/JCO.2005.09.051","DOI":"10.1200\/JCO.2005.09.051"},{"key":"1491_CR20","doi-asserted-by":"crossref","unstructured":"Buck AK, Serfling SE, Lindner T, H\u00e4nscheid H, Schirbel A, Hahner S, et al. CXCR4-targeted theranostics in oncology. Eur J Nucl Med Mol Imaging. Springer; 2022;49:4133\u201344.","DOI":"10.1007\/s00259-022-05849-y"},{"key":"1491_CR21","doi-asserted-by":"crossref","unstructured":"Buck AK, Grigoleit GU, Kraus S, Schirbel A, Heinsch M, Dreher N, et al. CXC motif chemokine receptor 4\u2013targeted radioligand therapy in patients with advanced T-cell lymphoma. J Nuclear Med. Soc Nuclear Med 2023;64:34\u20139.","DOI":"10.2967\/jnumed.122.264207"},{"key":"1491_CR22","doi-asserted-by":"publisher","unstructured":"Butcher DR, Parris CN, Crichton SJ, Dempsey FC, Al-Ali HN. Unlocking the potential of targeting the angiotensin II type 1 receptor in cancer. Oncogene. 2025. https:\/\/doi.org\/10.1038\/s41388-025-03666-9.","DOI":"10.1038\/s41388-025-03666-9"},{"key":"1491_CR23","doi-asserted-by":"publisher","unstructured":"Byun S, Affolter KE, Snow AK, Curtin K, Cannon AR, Cannon-Albright LA, et al. Differential methylation of G-protein coupled receptor signaling genes in gastrointestinal neuroendocrine tumors. Sci Rep. 2021;11. https:\/\/doi.org\/10.1038\/s41598-021-91934-5","DOI":"10.1038\/s41598-021-91934-5"},{"key":"1491_CR24","doi-asserted-by":"publisher","unstructured":"Cacan E. Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells. J Chemother. 2017;29. https:\/\/doi.org\/10.1080\/1120009X.2016.1277007","DOI":"10.1080\/1120009X.2016.1277007"},{"key":"1491_CR25","doi-asserted-by":"publisher","unstructured":"Cai K, Zhu Y, Zheng Y, Wang H, Qian Y. B2R-Targeting radiotracer for PET\/MR imaging of hepatocellular carcinoma and guiding anti-B2R therapy. ACS Med Chem Lett. 2024. https:\/\/doi.org\/10.1021\/acsmedchemlett.4c00155.","DOI":"10.1021\/acsmedchemlett.4c00155"},{"key":"1491_CR26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.196725","volume":"104","author":"N Casagrande","year":"2018","unstructured":"Casagrande N, Borghese C, Visser L, Mongiat M, Colombatti A, Aldinucci D. CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth. Haematologica. 2018;104:564.","journal-title":"Haematologica"},{"key":"1491_CR27","doi-asserted-by":"publisher","unstructured":"Casamassimi A, Ciccodicola A. Transcriptional regulation: molecules, involved mechanisms, and misregulation. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20061281.","DOI":"10.3390\/ijms20061281"},{"key":"1491_CR28","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/neuros\/nyz310_806","volume":"66","author":"KK Chahal","year":"2019","unstructured":"Chahal KK, Li J, Kufareva I, Durden D, Reya RW, Abagyan R, et al. Dynamic structural modeling revealed That nilotinib inhibits smoothened signaling. Neurosurgery LWW. 2019;66:310\u2013806.","journal-title":"Neurosurgery LWW"},{"key":"1491_CR29","doi-asserted-by":"crossref","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. Mass Medical Soc; 2022;387:2232\u201344.","DOI":"10.1056\/NEJMoa2204591"},{"key":"1491_CR30","doi-asserted-by":"publisher","unstructured":"Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1\u20132 study. Lancet Haematol. 2025;12. https:\/\/doi.org\/10.1016\/S2352-3026(24)00385-5","DOI":"10.1016\/S2352-3026(24)00385-5"},{"key":"1491_CR31","doi-asserted-by":"publisher","unstructured":"Chaudhary PK, Kim S. An insight into gpcr and g-proteins as cancer drivers. Cells. 2021 https:\/\/doi.org\/10.3390\/cells10123288","DOI":"10.3390\/cells10123288"},{"key":"1491_CR32","doi-asserted-by":"crossref","unstructured":"Chen Y, Liu C, Zhu S, Liang X, Zhang Q, Luo X, et al. PD-1\/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer. Int Immunopharmacol. Elsevier; 2021;96:107607.","DOI":"10.1016\/j.intimp.2021.107607"},{"key":"1491_CR33","doi-asserted-by":"publisher","unstructured":"Chen Q, Tesmer JJG. G protein\u2013coupled receptor interactions with arrestins and GPCR kinases: the unresolved issue of signal bias. J Biol Chem. 2022. https:\/\/doi.org\/10.1016\/j.jbc.2022.102279.","DOI":"10.1016\/j.jbc.2022.102279"},{"key":"1491_CR34","doi-asserted-by":"crossref","unstructured":"Choi SB, Lee HT, Gu N, Jang Y-J, Park UB, Jeong TJ, et al. Structural insights into the ADCC mechanism and resistance of Mogamulizumab, a first-in-class anti-CCR4 therapy for cutaneous T cell Lymphoma. Int J Mol Sci. Multidiscipl Digit Publish Institute; 2025;26:5500.","DOI":"10.3390\/ijms26125500"},{"key":"1491_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-89882-5","volume":"15","author":"NG Ciavattone","year":"2025","unstructured":"Ciavattone NG, Bevoor A, Farfel A, Rehman A, Ho KKY, Rock EC, et al. Inhibiting CXCR4 reduces immunosuppressive effects of myeloid cells in breast cancer immunotherapy. Sci Rep. 2025;15:5204. https:\/\/doi.org\/10.1038\/s41598-025-89882-5.","journal-title":"Sci Rep"},{"key":"1491_CR36","doi-asserted-by":"publisher","unstructured":"Cojoc M, Peitzsch C, Trautmann F, Polishchuk L, Telegeev GD, Dubrovska A. Emerging targets in cancer management: role of the CXCL12\/CXCR4 axis. Onco Targets Ther. 2013. https:\/\/doi.org\/10.2147\/OTT.S36109.","DOI":"10.2147\/OTT.S36109"},{"key":"1491_CR37","doi-asserted-by":"publisher","unstructured":"Crees ZD, Rettig MP, Jayasinghe RG, Stockerl-Goldstein K, Larson SM, Arpad I, et al. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med. 2023a. https:\/\/doi.org\/10.1038\/s41591-023-02273-z.","DOI":"10.1038\/s41591-023-02273-z"},{"key":"1491_CR38","doi-asserted-by":"publisher","unstructured":"Crees ZD, Rettig MP, DiPersio JF. Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide. Ther Adv Hematol. 2023b. https:\/\/doi.org\/10.1177\/20406207231174304.","DOI":"10.1177\/20406207231174304"},{"key":"1491_CR39","doi-asserted-by":"publisher","unstructured":"Crone SG, Jacobsen A, Federspiel B, Bardram L, Krogh A, Lund AH, et al. MicroRNA-146a inhibits G protein-coupled receptor-mediated activation of NF-\u03baB by targeting CARD10 and COPS8 in gastric cancer. Mol Cancer. 2012;11. https:\/\/doi.org\/10.1186\/1476-4598-11-71","DOI":"10.1186\/1476-4598-11-71"},{"key":"1491_CR40","doi-asserted-by":"publisher","unstructured":"Desale SE, Chidambaram H, Chinnathambi S. G-protein coupled receptor, PI3K and Rho signaling pathways regulate the cascades of Tau and amyloid-\u03b2 in Alzheimer\u2019s disease. Mol Biomed. 2021. https:\/\/doi.org\/10.1186\/s43556-021-00036-1.","DOI":"10.1186\/s43556-021-00036-1"},{"key":"1491_CR41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrc2069","volume":"7","author":"RT Dorsam","year":"2007","unstructured":"Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7:79\u201394. https:\/\/doi.org\/10.1038\/nrc2069.","journal-title":"Nat Rev Cancer"},{"key":"1491_CR42","doi-asserted-by":"publisher","unstructured":"Drozdz MM, Doane AS, Alkallas R, Desman G, Bareja R, Reilly M, et al. A nuclear cAMP microdomain suppresses tumor growth by Hippo pathway inactivation. Cell Rep. 2022;40. https:\/\/doi.org\/10.1016\/j.celrep.2022.111412","DOI":"10.1016\/j.celrep.2022.111412"},{"key":"1491_CR43","doi-asserted-by":"publisher","unstructured":"Dubuc C, Savard M, Bovenzi V, Lessard A, Fortier A, C\u00f4t\u00e9 J, et al. Targeting intracellular B2 receptors using novel cell-penetrating antagonists to arrest growth and induce apoptosis in human triple-negative breast cancer. Oncotarget. 2018. https:\/\/doi.org\/10.18632\/oncotarget.24009.","DOI":"10.18632\/oncotarget.24009"},{"key":"1491_CR44","doi-asserted-by":"publisher","unstructured":"Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of radiolabeled somatostatin analogs for cancer imaging and therapy. Molecules. 2020. https:\/\/doi.org\/10.3390\/molecules25174012.","DOI":"10.3390\/molecules25174012"},{"key":"1491_CR45","doi-asserted-by":"publisher","unstructured":"Follo MY, Manzoli L, Poli A, McCubrey JA, Cocco L. PLC and PI3K\/Akt\/mTOR signalling in disease and cancer. Adv Biol Regul. 2015. https:\/\/doi.org\/10.1016\/j.jbior.2014.10.004.","DOI":"10.1016\/j.jbior.2014.10.004"},{"key":"1491_CR46","doi-asserted-by":"publisher","first-page":"9511","DOI":"10.3390\/ijms21249511","volume":"21","author":"F Fontana","year":"2020","unstructured":"Fontana F, Marzagalli M, Montagnani Marelli M, Raimondi M, Moretti RM, Limonta P. Gonadotropin-releasing hormone receptors in prostate cancer: molecular aspects and biological functions. Int J Mol Sci. 2020;21:9511 MDPI.","journal-title":"Int J Mol Sci"},{"key":"1491_CR47","doi-asserted-by":"publisher","unstructured":"Francica BJ, Holtz A, Lopez J, Freund D, Chen A, Wang D, et al. Dual blockade of EP2 and EP4 signaling is required for optimal immune activation and antitumor activity against prostaglandin-expressing tumors. Cancer Res Commun. 2023. https:\/\/doi.org\/10.1158\/2767-9764.CRC-23-0249.","DOI":"10.1158\/2767-9764.CRC-23-0249"},{"key":"1491_CR48","doi-asserted-by":"publisher","unstructured":"Fredriksson R, Schi\u00f6th HB. The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol. 2005;67. https:\/\/doi.org\/10.1124\/mol.104.009001","DOI":"10.1124\/mol.104.009001"},{"key":"1491_CR49","doi-asserted-by":"publisher","unstructured":"Freeman JL, Perry GH, Feuk L, Redon R, McCarroll SA, Altshuler DM, et al. Copy number variation: new insights in genome diversity. Genome Res. 2006. https:\/\/doi.org\/10.1101\/gr.3677206.","DOI":"10.1101\/gr.3677206"},{"key":"1491_CR50","doi-asserted-by":"publisher","unstructured":"Ghobrial IM, Liu CJ, Redd RA, Perez RP, Baz R, Zavidij O, et al. A phase Ib\/II trial of the first-in-class anti-CXCR4 antibody ulocuplumab in combination with lenalidomide or bortezomib plus dexamethasone in relapsed multiple myeloma. Clin Cancer Res. 2020. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0647.","DOI":"10.1158\/1078-0432.CCR-19-0647"},{"key":"1491_CR51","doi-asserted-by":"publisher","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023. https:\/\/doi.org\/10.1186\/s12943-023-01827-6.","DOI":"10.1186\/s12943-023-01827-6"},{"key":"1491_CR52","doi-asserted-by":"crossref","unstructured":"Goldman J, Eckhardt SG, Borad MJ, Curtis KK, Hidalgo M, Calvo E, et al. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. Clinical cancer research. American Association for Cancer Research; 2015;21:1002\u20139.","DOI":"10.1158\/1078-0432.CCR-14-1234"},{"key":"1491_CR53","doi-asserted-by":"publisher","unstructured":"Goldstein LJ, Mansutti M, Levy C, Chang JC, Henry S, Fernandez-Perez I, et al. A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida). Breast Cancer Res Treat. 2021. https:\/\/doi.org\/10.1007\/s10549-021-06367-5.","DOI":"10.1007\/s10549-021-06367-5"},{"key":"1491_CR54","doi-asserted-by":"publisher","unstructured":"Gorica J, De Feo MS, Corica F, Sidrak MMA, Conte M, Filippi L, et al. Novel theranostic approaches targeting CCR4-Receptor, current status and translational prospectives: a systematic review. Pharmaceuticals. 2023. https:\/\/doi.org\/10.3390\/ph16020313.","DOI":"10.3390\/ph16020313"},{"key":"1491_CR55","doi-asserted-by":"publisher","unstructured":"Grazioli E, Dimauro I, Mercatelli N, Wang G, Pitsiladis Y, Di Luigi L, et al. Physical activity in the prevention of human diseases: role of epigenetic modifications. BMC Genomics. 2017. https:\/\/doi.org\/10.1186\/s12864-017-4193-5.","DOI":"10.1186\/s12864-017-4193-5"},{"key":"1491_CR56","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/carcin\/bgp014","volume":"30","author":"A Greenhough","year":"2009","unstructured":"Greenhough A, Smartt HJM, Moore AE, Roberts HR, Williams AC, Paraskeva C, et al. The COX-2\/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009;30:377\u201386. https:\/\/doi.org\/10.1093\/carcin\/bgp014.","journal-title":"Carcinogenesis"},{"key":"1491_CR57","doi-asserted-by":"publisher","unstructured":"Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012. https:\/\/doi.org\/10.1038\/nrg3173.","DOI":"10.1038\/nrg3173"},{"key":"1491_CR58","doi-asserted-by":"publisher","unstructured":"Growcott JW. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054. Anticancer Drugs. 2009. https:\/\/doi.org\/10.1097\/CAD.0b013e328320791c.","DOI":"10.1097\/CAD.0b013e328320791c"},{"key":"1491_CR59","doi-asserted-by":"publisher","unstructured":"Gu M, Ren B, Fang Y, Ren J, Liu X, Wang X, et al. Epigenetic regulation in cancer. MedComm. 2024. https:\/\/doi.org\/10.1002\/mco2.495.","DOI":"10.1002\/mco2.495"},{"key":"1491_CR60","doi-asserted-by":"publisher","unstructured":"von Guggenberg E, Uprimny C, Klinger M, Warwitz B, Sviridenko A, Bayerschmidt S, et al. Preliminary clinical experience with cholecystokinin-2 receptor PET\/CT Using the 68Ga-Labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer. J Nuclear Med 2023;64. https:\/\/doi.org\/10.2967\/jnumed.122.264977","DOI":"10.2967\/jnumed.122.264977"},{"key":"1491_CR61","doi-asserted-by":"publisher","unstructured":"Guieu R, Degioanni C, Fromonot J, De Maria L, Ruf J, Deharo JC, et al. Adenosine, adenosine receptors and neurohumoral syncope: from molecular basis to personalized treatment. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10051127.","DOI":"10.3390\/biomedicines10051127"},{"key":"1491_CR62","doi-asserted-by":"publisher","unstructured":"Guo Y, Pan W, Liu S, Shen Z, Xu Y, Hu L. ERK\/MAPK signalling pathway and tumorigenesis (Review). Exp Ther Med. 2020. https:\/\/doi.org\/10.3892\/etm.2020.8454.","DOI":"10.3892\/etm.2020.8454"},{"key":"1491_CR63","doi-asserted-by":"crossref","unstructured":"Halvorsen EC, Hamilton MJ, Young A, Wadsworth BJ, LePard NE, Lee H-N, et al. Maraviroc decreases CCL8-mediated migration of CCR5+ regulatory T cells and reduces metastatic tumor growth in the lungs. Oncoimmunology. Taylor & Francis; 2016;5:e1150398.","DOI":"10.1080\/2162402X.2016.1150398"},{"key":"1491_CR64","doi-asserted-by":"publisher","unstructured":"Harmon C, Robinson MW, Hand F, Almuaili D, Mentor K, Houlihan DD, et al. Lactate-mediated acidification of tumor microenvironment induces apoptosis of liver-resident NK cells in colorectal liver metastasis. Cancer Immunol Res. 2019. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0481.","DOI":"10.1158\/2326-6066.CIR-18-0481"},{"key":"1491_CR65","doi-asserted-by":"publisher","unstructured":"Hayes MP, Roman DL. Regulator of G protein signaling 17 as a negative modulator of GPCR signaling in multiple human cancers. AAPS J. 2016. https:\/\/doi.org\/10.1208\/s12248-016-9894-1.","DOI":"10.1208\/s12248-016-9894-1"},{"key":"1491_CR66","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/ph12030114","volume":"12","author":"U Hennrich","year":"2019","unstructured":"Hennrich U, Kopka K. Lutathera\u00ae: the first FDA-and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals Basel. 2019a;12:114 MDPI.","journal-title":"Pharmaceuticals Basel"},{"key":"1491_CR67","doi-asserted-by":"publisher","unstructured":"Hennrich U, Kopka K. Lutathera\u00ae: the first FDA-and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals. 2019b. https:\/\/doi.org\/10.3390\/ph12030114.","DOI":"10.3390\/ph12030114"},{"key":"1491_CR68","doi-asserted-by":"publisher","unstructured":"Hilger D. The role of structural dynamics in GPCR-mediated signaling. FEBS J. 2021. https:\/\/doi.org\/10.1111\/febs.15841.","DOI":"10.1111\/febs.15841"},{"key":"1491_CR69","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1096\/fj.14-267849","volume":"29","author":"L Hoch","year":"2015","unstructured":"Hoch L, Faure H, Roudaut H, Schoenfelder A, Mann A, Girard N, et al. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor. FASEB J. 2015;29:1817.","journal-title":"FASEB J"},{"key":"1491_CR70","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2020.01.009","volume":"474","author":"H Huang","year":"2020","unstructured":"Huang H, Zepp M, Georges RB, Jarahian M, Kazemi M, Eyol E, et al. The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction. Cancer Lett Elsevier. 2020;474:82\u201393.","journal-title":"Cancer Lett Elsevier"},{"key":"1491_CR71","doi-asserted-by":"publisher","unstructured":"Huang X, Hao J, Tan YQ, Zhu T, Pandey V, Lobie PE. CXC Chemokine signaling in progression of epithelial ovarian cancer: theranostic perspectives. Int J Mol Sci. 2022;23. https:\/\/doi.org\/10.3390\/ijms23052642","DOI":"10.3390\/ijms23052642"},{"key":"1491_CR72","doi-asserted-by":"publisher","unstructured":"Hwang CK, Law PY, Wei LN, Loh HH. Regulation of the transcription of G protein-coupled receptor genes. Neuromethods. 2011;60. https:\/\/doi.org\/10.1007\/978-1-61779-179-6_4","DOI":"10.1007\/978-1-61779-179-6_4"},{"key":"1491_CR73","doi-asserted-by":"publisher","unstructured":"Insel PA, Tang CM, Hahntow I, Michel MC. Impact of GPCRs in clinical medicine: Monogenic diseases, genetic variants and drug targets. Biochim. Biophys. Acta Biomembr. 2007 https:\/\/doi.org\/10.1016\/j.bbamem.2006.09.029","DOI":"10.1016\/j.bbamem.2006.09.029"},{"key":"1491_CR74","doi-asserted-by":"publisher","unstructured":"Itcho K, Oki K, Kobuke K, Yoshii Y, Ohno H, Yoneda M, et al. Aberrant G protein-receptor expression is associated with DNA methylation in aldosterone-producing adenoma. Mol Cell Endocrinol. 2018;461. https:\/\/doi.org\/10.1016\/j.mce.2017.08.019","DOI":"10.1016\/j.mce.2017.08.019"},{"key":"1491_CR75","doi-asserted-by":"crossref","unstructured":"J. R, D. H, A. F. Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev 2011;30.","DOI":"10.1007\/s10555-011-9303-2"},{"key":"1491_CR76","doi-asserted-by":"crossref","unstructured":"Jain S, Song R, Xie J. Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas. Onco Targets Ther. Taylor & Francis; 2017;1645\u201353.","DOI":"10.2147\/OTT.S130910"},{"key":"1491_CR77","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/2643-3230.BCD-20-0007","volume":"1","author":"C Jamieson","year":"2020","unstructured":"Jamieson C, Martinelli G, Papayannidis C, Cortes JE. Hedgehog pathway inhibitors: a new therapeutic class for the treatment of acute myeloid leukemia. Blood Cancer Discov. 2020;1:134\u201345 Ame Assoc Cancer Res.","journal-title":"Blood Cancer Discov"},{"key":"1491_CR78","doi-asserted-by":"publisher","unstructured":"Jiao X, Wang M, Zhang Z, Li Z, Ni D, Ashton AW, et al. Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. Breast Cancer Res. 2021. https:\/\/doi.org\/10.1186\/s13058-021-01391-1.","DOI":"10.1186\/s13058-021-01391-1"},{"key":"1491_CR79","doi-asserted-by":"publisher","unstructured":"Jiao X, Nawab O, Patel T, Kossenkov A V., Halama N, Jaeger D, et al. Recent advances targeting CCR5 for cancer and its role in immuno-oncology. Cancer Res. 2019;79. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-1167","DOI":"10.1158\/0008-5472.CAN-19-1167"},{"key":"1491_CR80","doi-asserted-by":"publisher","unstructured":"Johnson B, Kopetz S, Hwang H, Yuan Y, DePinho RA, Zebala J, et al. STOPTRAFFIC-1: a phase I\/II trial of SX-682 in combination with nivolumab for refractory RAS- mutated microsatellite stable (MSS) metastatic colorectal cancer (mCRC). . J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.tps3638.","DOI":"10.1200\/jco.2022.40.16_suppl.tps3638"},{"key":"1491_CR81","doi-asserted-by":"publisher","unstructured":"Justus CR, Dong L, Yang LV. Acidic tumor microenvironment and pH-sensing G protein-coupled receptors. Front Physiol. 2013. https:\/\/doi.org\/10.3389\/fphys.2013.00354.","DOI":"10.3389\/fphys.2013.00354"},{"key":"1491_CR82","doi-asserted-by":"publisher","unstructured":"Kanemaru K, Nakamura Y. Activation mechanisms and diverse functions of mammalian phospholipase C. Biomolecules. 2023. https:\/\/doi.org\/10.3390\/biom13060915.","DOI":"10.3390\/biom13060915"},{"key":"1491_CR83","doi-asserted-by":"publisher","unstructured":"Kang J-H. Protein Kinase C (PKC) Isozymes and Cancer. New J Sci. 2014;2014. https:\/\/doi.org\/10.1155\/2014\/231418","DOI":"10.1155\/2014\/231418"},{"key":"1491_CR84","doi-asserted-by":"crossref","unstructured":"Kapeni C, O\u2019Brien L, Sabirova D, Cast O, Carbonaro V, Clark-Leonard S, et al. Noncanonical Hedgehog signaling through Smoothened controls cytotoxic T cell migration in the tumor microenvironment. Sci Immunol. American Association for the Advancement of Science; 2025;10:eadr3127.","DOI":"10.1126\/sciimmunol.adr3127"},{"key":"1491_CR85","doi-asserted-by":"publisher","unstructured":"Katan M, Cockcroft S. Phosphatidylinositol(4,5)bisphosphate: diverse functions at the plasma membrane. Essays Biochem. 2020. https:\/\/doi.org\/10.1042\/EBC20200041.","DOI":"10.1042\/EBC20200041"},{"key":"1491_CR86","doi-asserted-by":"publisher","unstructured":"Katritch V, Cherezov V, Stevens RC. Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol. Sci. 2012 https:\/\/doi.org\/10.1016\/j.tips.2011.09.003","DOI":"10.1016\/j.tips.2011.09.003"},{"key":"1491_CR87","first-page":"1623","volume":"71","author":"GM Keating","year":"2011","unstructured":"Keating GM. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs Springer. 2011;71:1623\u201347.","journal-title":"Drugs Springer"},{"key":"1491_CR88","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/sj.onc.1208237","volume":"24","author":"TH Kim","year":"2005","unstructured":"Kim TH, Xiong H, Zhang Z, Ren B. \u03b2-Catenin activates the growth factor endothelin-1 in colon cancer cells. Oncogene. 2005;24:597\u2013604. https:\/\/doi.org\/10.1038\/sj.onc.1208237.","journal-title":"Oncogene"},{"key":"1491_CR89","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ccr.2010.02.027","volume":"17","author":"J Kim","year":"2010","unstructured":"Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell Elsevier. 2010;17:388\u201399.","journal-title":"Cancer Cell Elsevier"},{"key":"1491_CR90","doi-asserted-by":"publisher","unstructured":"Kim K, Han Y, Duan L, Chung KY. Scaffolding of mitogen-activated protein kinase signaling by \u03b2-Arrestins. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23021000.","DOI":"10.3390\/ijms23021000"},{"key":"1491_CR91","doi-asserted-by":"publisher","unstructured":"Korbecki J, Bosiacki M, Pilarczyk M, Kot M, Defort P, Walaszek I, et al. The CXCL1-CXCR2 axis as a component of therapy resistance, a source of side effects in cancer treatment, and a therapeutic target. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17101674.","DOI":"10.3390\/cancers17101674"},{"key":"1491_CR92","doi-asserted-by":"publisher","unstructured":"Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M, et al. Prostaglandin E2 activates mitogen-activated protein kinase\/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res. 2005. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-0216.","DOI":"10.1158\/0008-5472.CAN-05-0216"},{"key":"1491_CR93","doi-asserted-by":"publisher","unstructured":"Lai SL, Chien AJ, Moon RT. Wnt\/Fz signaling and the cytoskeleton: Potential roles in tumorigenesis. Cell Res. 2009;19. https:\/\/doi.org\/10.1038\/cr.2009.41","DOI":"10.1038\/cr.2009.41"},{"key":"1491_CR94","doi-asserted-by":"crossref","unstructured":"Lappano R, Maggiolini M. Pharmacotherapeutic targeting of G protein-coupled receptors in oncology: examples of approved therapies and emerging concepts. Drugs. 2017;77:951\u201365 Springer.","DOI":"10.1007\/s40265-017-0738-9"},{"key":"1491_CR95","doi-asserted-by":"publisher","unstructured":"Lesage A, Gibson C, Marceau F, Ambrosi HD, Saupe J, Katzer W, et al. In vitro pharmacological profile of a new small molecule Bradykinin B2 receptor antagonist. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/fphar.2020.00916.","DOI":"10.3389\/fphar.2020.00916"},{"key":"1491_CR96","doi-asserted-by":"publisher","unstructured":"Li T, Ao ECI, Lambert B, Brans B, Vandenberghe S, Mok GSP. Quantitative imaging for targeted radionuclide therapy dosimetry - Technical review. Theranostics. 2017. https:\/\/doi.org\/10.7150\/thno.19782.","DOI":"10.7150\/thno.19782"},{"key":"1491_CR97","doi-asserted-by":"publisher","unstructured":"Li S, Chen J, Chen X, Yu J, Guo Y, Li M, et al. Therapeutic and prognostic potential of GPCRs in prostate cancer from multi-omics landscape. Front Pharmacol. 2022;13. https:\/\/doi.org\/10.3389\/fphar.2022.997664","DOI":"10.3389\/fphar.2022.997664"},{"key":"1491_CR98","unstructured":"Liguori NR, Sanchez Sevilla Uruchurtu A, Zhang L, Abbas AE, Lee YS, Zhou L, et al. Preclinical studies with ONC201\/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC). Am J Cancer Res. 2022;12."},{"key":"1491_CR99","doi-asserted-by":"publisher","unstructured":"Lin YH, Lin YC, Chen CC. Lysophosphatidic acid receptor antagonists and cancer: the current trends, clinical implications, and trials. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10071629.","DOI":"10.3390\/cells10071629"},{"key":"1491_CR100","doi-asserted-by":"publisher","unstructured":"Linehan D, Noel MS, Hezel AF, Wang-Gillam A, Eskens F, Sleijfer S, et al. Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced\/metastatic pancreatic cancer: correlation with blood monocyte counts. J Clin Oncol. 2018. https:\/\/doi.org\/10.1200\/jco.2018.36.5_suppl.92.","DOI":"10.1200\/jco.2018.36.5_suppl.92"},{"key":"1491_CR101","doi-asserted-by":"publisher","unstructured":"Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022. https:\/\/doi.org\/10.1038\/s41392-021-00762-6.","DOI":"10.1038\/s41392-021-00762-6"},{"key":"1491_CR102","doi-asserted-by":"publisher","unstructured":"Liu YT, Wang YL, Wang S, Li JJ, He W, Fan XJ, et al. Turning cold tumors into hot tumors to ignite immunotherapy. Mol Cancer. 2025. https:\/\/doi.org\/10.1186\/s12943-025-02477-6.","DOI":"10.1186\/s12943-025-02477-6"},{"key":"1491_CR103","doi-asserted-by":"publisher","unstructured":"Lorente JS, Sokolov AV, Ferguson G, Schi\u00f6th HB, Hauser AS, Gloriam DE. GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2025. https:\/\/doi.org\/10.1038\/s41573-025-01139-y.","DOI":"10.1038\/s41573-025-01139-y"},{"key":"1491_CR104","doi-asserted-by":"publisher","unstructured":"Lu YY, Sweredoski MJ, Huss D, Lansford R, Hess S, Tirrell DA. Prometastatic GPCR CD97 is a direct target of tumor suppressor microRNA-126. ACS Chem Biol. 2014. https:\/\/doi.org\/10.1021\/cb400704n.","DOI":"10.1021\/cb400704n"},{"key":"1491_CR105","doi-asserted-by":"publisher","unstructured":"Luo M, Zhu J, Ren J, Tong Y, Wang L, Ma S, et al. Lactate increases tumor malignancy by promoting tumor small extracellular vesicles production via the GPR81-cAMP-PKA-HIF-1\u03b1 axis. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.1036543.","DOI":"10.3389\/fonc.2022.1036543"},{"key":"1491_CR106","doi-asserted-by":"publisher","unstructured":"Machado JF, Silva RD, Melo R, Correia JDG. Less exploited GPCRs in precision medicine: Targets for molecular imaging and theranostics. Molecules. 2019. https:\/\/doi.org\/10.3390\/molecules24010049.","DOI":"10.3390\/molecules24010049"},{"key":"1491_CR107","doi-asserted-by":"crossref","unstructured":"Maher TM, Molyneaux PL, Goldin JG, Huetsch JC, Difrancesco A, De Los Rios M, et al. WHISTLE-PF: Study design of a phase 2b, multi-center, randomized, double-blind, controlled trial of ENV-101 (Taladegib) in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. Am Thor Soc; 2025;211:A2634\u2013A2634.","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A2634"},{"key":"1491_CR108","doi-asserted-by":"publisher","unstructured":"Malbon CC. Beta-catenin, cancer, and G proteins: not just for frizzleds anymore. Sci STKE. 2005. https:\/\/doi.org\/10.1126\/stke.2922005pe35.","DOI":"10.1126\/stke.2922005pe35"},{"key":"1491_CR109","doi-asserted-by":"publisher","unstructured":"Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat Biotechnol. 2003. https:\/\/doi.org\/10.1038\/nbt0303-255.","DOI":"10.1038\/nbt0303-255"},{"key":"1491_CR110","doi-asserted-by":"crossref","unstructured":"Martin M, Mayer IA, Walenkamp AME, Lapa C, Andreeff M, Bobirca A. At the Bedside: Profiling and treating patients with CXCR4-expressing cancers. J Leucocyte Biol. Oxford University Press; 2021;109:953\u201367.","DOI":"10.1002\/JLB.5BT1219-714R"},{"key":"1491_CR111","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez-Morales JC, Sol\u00eds KH, Romero-\u00c1vila MT, Reyes-Cruz G, Garc\u00eda-S\u00e1inz JA. Cell trafficking and function of G protein-coupled receptors. Arch Med Res. 2022. https:\/\/doi.org\/10.1016\/j.arcmed.2022.06.008.","DOI":"10.1016\/j.arcmed.2022.06.008"},{"key":"1491_CR112","doi-asserted-by":"publisher","unstructured":"Mattei J, Achcar RD, Cano CH, Macedo BR, Meurer L, Batlle BS, et al. Gastrin-releasing peptide receptor expression in lung cancer. Arch Pathol Lab Med. 2014. https:\/\/doi.org\/10.5858\/arpa.2012-0679-OA.","DOI":"10.5858\/arpa.2012-0679-OA"},{"key":"1491_CR113","doi-asserted-by":"publisher","unstructured":"Matters GL, Harms JF. Utilizing peptide ligand GPCRs to image and treat pancreatic cancer. Biomedicines. 2018. https:\/\/doi.org\/10.3390\/biomedicines6020065.","DOI":"10.3390\/biomedicines6020065"},{"key":"1491_CR114","doi-asserted-by":"crossref","unstructured":"Meiss F, Andrlov\u00e1 H, Zeiser R. Vismodegib. Small molecules in Oncology. Springer; 2018;125\u201339.","DOI":"10.1007\/978-3-319-91442-8_9"},{"key":"1491_CR115","doi-asserted-by":"crossref","unstructured":"Mej\u00eda-Rodr\u00edguez R, Romero-Trejo D, Gonz\u00e1lez RO, Segovia J. Combined treatments with AZD5363, AZD8542, curcumin or resveratrol induce death of human glioblastoma cells by suppressing the PI3K\/AKT and SHH signaling pathways. Biochem Biophys Rep. Elsevier; 2023;33:101430.","DOI":"10.1016\/j.bbrep.2023.101430"},{"key":"1491_CR116","doi-asserted-by":"crossref","unstructured":"Mezzapelle R, Leo M, Caprioglio F, Colley LS, Lamarca A, Sabatino L, et al. CXCR4\/CXCL12 activities in the tumor microenvironment and implications for tumor immunotherapy. Cancers (Basel). MDPI; 2022;14:2314.","DOI":"10.3390\/cancers14092314"},{"key":"1491_CR117","doi-asserted-by":"publisher","first-page":"156","DOI":"10.36849\/JDD.5657","volume":"20","author":"MD Michael Migden","year":"2021","unstructured":"Michael Migden MD, Farberg AS, Dummer BR, Nicholas Squittieri MD. A review of hedgehog inhibitors sonidegib and vismodegib for treatment of advanced basal cell carcinoma. J Drugs Dermatol. 2021;20:156\u201365.","journal-title":"J Drugs Dermatol"},{"key":"1491_CR118","first-page":"1","volume":"25","author":"M Mohty","year":"2011","unstructured":"Mohty M, Duarte RF, Croockewit S, H\u00fcbel K, Kvalheim G, Russell N. The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia Nature Publishing Group. 2011;25:1\u20136.","journal-title":"Leukemia Nature Publishing Group"},{"key":"1491_CR119","doi-asserted-by":"publisher","unstructured":"Moore AR, Boyce M, Steele IA, Campbell F, Varro A, Pritchard DM. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS One. 2013;8. https:\/\/doi.org\/10.1371\/journal.pone.0076462","DOI":"10.1371\/journal.pone.0076462"},{"key":"1491_CR120","doi-asserted-by":"crossref","unstructured":"Morland B, Kepak T, Dallorso S, Sevilla J, Murphy D, Luksch R, et al. Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I\/II study (MOZAIC). Bone Marrow Transplant. Nature Publishing Group UK London; 2020;55:1744\u201353.","DOI":"10.1038\/s41409-020-0836-2"},{"key":"1491_CR121","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.3390\/ijms23031733","volume":"23","author":"NM Nguyen","year":"2022","unstructured":"Nguyen NM, Cho J. Hedgehog pathway inhibitors as targeted cancer therapy and strategies to overcome drug resistance. Int J Mol Sci. 2022;23:1733 (MDPI).","journal-title":"Int J Mol Sci"},{"key":"1491_CR122","doi-asserted-by":"publisher","unstructured":"Nock BA, Kanellopoulos P, Joosten L, Mansi R, Maina T. Peptide radioligands in cancer theranostics: agonists and antagonists. Pharmaceuticals Basel. 2023. https:\/\/doi.org\/10.3390\/ph16050674.","DOI":"10.3390\/ph16050674"},{"key":"1491_CR123","doi-asserted-by":"crossref","unstructured":"Norsworthy KJ, By K, Subramaniam S, Zhuang L, Del Valle PL, Przepiorka D, et al. FDA approval summary: glasdegib for newly diagnosed acute myeloid leukemia. Clinical Cancer Research. American Association for Cancer Research; 2019;25:6021\u20135.","DOI":"10.1158\/1078-0432.CCR-19-0365"},{"key":"1491_CR124","doi-asserted-by":"publisher","unstructured":"O\u2019Hayre M, V\u00e1zquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer. 2013;13. https:\/\/doi.org\/10.1038\/nrc3521","DOI":"10.1038\/nrc3521"},{"key":"1491_CR125","doi-asserted-by":"crossref","unstructured":"Ollila TA, Sahin I, Olszewski AJ. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma. Onco Targets Ther. Taylor & Francis; 2019;1085\u201394.","DOI":"10.2147\/OTT.S165615"},{"key":"1491_CR126","doi-asserted-by":"publisher","unstructured":"Orange ST, Leslie J, Ross M, Mann DA, Wackerhage H. The exercise IL-6 enigma in cancer. Trends Endocrinol Metab. 2023. https:\/\/doi.org\/10.1016\/j.tem.2023.08.001.","DOI":"10.1016\/j.tem.2023.08.001"},{"key":"1491_CR127","doi-asserted-by":"publisher","unstructured":"Otsuka S, Bebb G. The CXCR4\/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer. J Thorac Oncol. 2008. https:\/\/doi.org\/10.1097\/JTO.0b013e31818dda9d.","DOI":"10.1097\/JTO.0b013e31818dda9d"},{"key":"1491_CR128","doi-asserted-by":"publisher","unstructured":"Pan P, Oshima K, Huang YW, Agle KA, Drobyski WR, Chen X, et al. Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. Int J Cancer. 2018;143. https:\/\/doi.org\/10.1002\/ijc.31366","DOI":"10.1002\/ijc.31366"},{"key":"1491_CR129","doi-asserted-by":"publisher","unstructured":"Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J. 2009;28. https:\/\/doi.org\/10.1038\/emboj.2008.304","DOI":"10.1038\/emboj.2008.304"},{"key":"1491_CR130","doi-asserted-by":"publisher","unstructured":"Parascandolo A, Castellone MD. Gastrin-Releasing Peptide Receptor (GRPR). Encyclopedia of signaling molecules. Cham: Springer International Publishing; 2018. p. 2022\u20137. https:\/\/doi.org\/10.1007\/978-3-319-67199-4_101646","DOI":"10.1007\/978-3-319-67199-4_101646"},{"key":"1491_CR131","doi-asserted-by":"publisher","unstructured":"Patel SP, Dimou A, Victor AI, Mooradian M, Buchbinder EI, Hernandez-Aya LF, et al. Safety and efficacy of first-in-class CXCR1\/2 inhibitor SX-682 in combination with Pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti\u2013PD-1 therapy. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.9508.","DOI":"10.1200\/jco.2024.42.16_suppl.9508"},{"key":"1491_CR132","doi-asserted-by":"publisher","unstructured":"Patny A, Desai PV, Avery MA. Ligand-supported homology modeling of the human angiotensin II type 1 (AT1) receptor: insights into the molecular determinants of telmisartan binding. Proteins. 2006. https:\/\/doi.org\/10.1002\/prot.21196.","DOI":"10.1002\/prot.21196"},{"key":"1491_CR133","doi-asserted-by":"crossref","unstructured":"Peer E, Tesanovic S, Aberger F. Next-generation Hedgehog\/GLI pathway inhibitors for cancer therapy. Cancers (Basel). MDPI; 2019;11:538.","DOI":"10.3390\/cancers11040538"},{"key":"1491_CR134","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s13402-018-0415-3","volume":"42","author":"A Pervaiz","year":"2019","unstructured":"Pervaiz A, Zepp M, Mahmood S, Ali DM, Berger MR, Adwan H. CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer. Cell Oncol Dordr. 2019;42:93\u2013106 Springer.","journal-title":"Cell Oncol Dordr"},{"key":"1491_CR135","doi-asserted-by":"publisher","unstructured":"Peterson AF, Ingram K, Huang EJ, Parksong J, McKenney C, Bever GS, et al. Systematic analysis of the MAPK signaling network reveals MAP3K-driven control of cell fate. Cell Syst. 2022;13. https:\/\/doi.org\/10.1016\/j.cels.2022.10.003","DOI":"10.1016\/j.cels.2022.10.003"},{"key":"1491_CR136","doi-asserted-by":"publisher","unstructured":"Pietrantonio F, Morano F, Niger M, Ghelardi F, Chiodoni C, Palazzo M, et al. Updated results and subgroup analysis by presence of liver metastases of a phase I\/II study of the EP4 antagonist vorbipiprant with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR\/MSS) chemorefractory metastatic colorectal cancer (mCRC). J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.3560.","DOI":"10.1200\/jco.2024.42.16_suppl.3560"},{"key":"1491_CR137","doi-asserted-by":"crossref","unstructured":"Pite\u0161a N, Kurtovi\u0107 M, Bartoni\u010dek N, Gkotsi DS, \u010conka\u0161 J, Petri\u0107 T, et al. Signaling switching from hedgehog-GLI to MAPK signaling potentially serves as a compensatory mechanism in melanoma cell lines resistant to GANT-61. Biomedicines. MDPI; 2023;11:1353.","DOI":"10.3390\/biomedicines11051353"},{"key":"1491_CR138","doi-asserted-by":"publisher","unstructured":"Poeta VM, Massara M, Capucetti A, Bonecchi R. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front Immunol. 2019. https:\/\/doi.org\/10.3389\/fimmu.2019.00379.","DOI":"10.3389\/fimmu.2019.00379"},{"key":"1491_CR139","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11912-015-0492-7","volume":"18","author":"VK Pokuri","year":"2016","unstructured":"Pokuri VK, Fong MK, Iyer R. Octreotide and lanreotide in gastroenteropancreatic neuroendocrine tumors. Curr Oncol Rep. 2016;18:7 Springer.","journal-title":"Curr Oncol Rep"},{"key":"1491_CR140","doi-asserted-by":"crossref","first-page":"pt7","DOI":"10.1126\/scisignal.2002396","volume":"4","author":"AH Polizio","year":"2011","unstructured":"Polizio AH, Chinchilla P, Chen X, Manning DR, Riobo NA. Sonic Hedgehog activates the GTPases Rac1 and RhoA in a Gli-independent manner through coupling of smoothened to Gi proteins. Sci Signal. 2011;4:pt7\u2013pt7 American Association for the Advancement of Science.","journal-title":"Sci Signal"},{"key":"1491_CR141","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.7150\/ijbs.59262","volume":"17","author":"J Qu","year":"2021","unstructured":"Qu J, Sun Z, Peng C, Li D, Yan W, Xu Z, et al. C. tropicalis promotes chemotherapy resistance in colon cancer through increasing lactate production to regulate the mismatch repair system. Int J Biol Sci. 2021;17:2756\u201369. https:\/\/doi.org\/10.7150\/ijbs.59262.","journal-title":"Int J Biol Sci"},{"key":"1491_CR142","doi-asserted-by":"publisher","unstructured":"Ramos-Espiritu L, Diaz A, Nardin C, Saviola AJ, Shaw F, Plitt T, et al. The metabolic\/pH sensor soluble adenylyl cyclase is a tumor suppressor protein. Oncotarget. 2016;7. https:\/\/doi.org\/10.18632\/oncotarget.10056","DOI":"10.18632\/oncotarget.10056"},{"key":"1491_CR143","doi-asserted-by":"crossref","unstructured":"Rashidi A, DiPersio JF. Targeting the leukemia\u2013stroma interaction in acute myeloid leukemia: rationale and latest evidence. Ther Adv Hematol. SAGE Publications Sage UK: London, England; 2016;7:40\u201351.","DOI":"10.1177\/2040620715619307"},{"key":"1491_CR144","doi-asserted-by":"publisher","unstructured":"Raymond JH, Aktary Z, Larue L, Delmas V. Targeting GPCRs and their signaling as a therapeutic option in melanoma. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14030706.","DOI":"10.3390\/cancers14030706"},{"key":"1491_CR145","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s12079-021-00652-0","volume":"16","author":"DAB Rex","year":"2022","unstructured":"Rex DAB, Deepak K, Vaid N, Dagamajalu S, Kandasamy RK, Flo TH, et al. A modular map of Bradykinin-mediated inflammatory signaling network. J Cell Commun Signal. 2022;16:301\u201310. https:\/\/doi.org\/10.1007\/s12079-021-00652-0.","journal-title":"J Cell Commun Signal"},{"key":"1491_CR146","doi-asserted-by":"crossref","unstructured":"Ribeiro JH, Villarinho NJ, Fernandes PV, Spohr TCL de S e, Lopes GP de F. Conditioned medium from reactive astrocytes inhibits proliferation, resistance, and migration of p53\u2010Mutant glioblastoma spheroid through GLI\u20101 downregulation. J Cell Biochem. Wiley Online Library; 2024;125:e30637.","DOI":"10.1002\/jcb.30637"},{"key":"1491_CR147","doi-asserted-by":"publisher","unstructured":"Ridley AJL, Dyer DP. Chemokine redundancy versus specificity in the context of CXCR3 and its ligands. Immunol Cell Biol. 2022. https:\/\/doi.org\/10.1111\/imcb.12553.","DOI":"10.1111\/imcb.12553"},{"key":"1491_CR148","doi-asserted-by":"publisher","unstructured":"Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, Cornax I, Vishwamitra D, Gray K, et al. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J. 2024. https:\/\/doi.org\/10.1038\/s41408-023-00966-9.","DOI":"10.1038\/s41408-023-00966-9"},{"key":"1491_CR149","doi-asserted-by":"crossref","unstructured":"Rohner A, Spilker ME, Lam JL, Pascual B, Bartkowski D, Li QJ, et al. Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood\u2013brain barrier. Mol Cancer Ther. Am Assoc Cancer Res 2012;11:57\u201365.","DOI":"10.1158\/1535-7163.MCT-11-0691"},{"key":"1491_CR150","doi-asserted-by":"publisher","unstructured":"Rosenbaum DM, Rasmussen SGF, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009. https:\/\/doi.org\/10.1038\/nature08144.","DOI":"10.1038\/nature08144"},{"key":"1491_CR151","doi-asserted-by":"publisher","unstructured":"Rottenburger C, Nicolas GP, McDougall L, Kaul F, Cachovan M, Vija AH, et al. Cholecystokinin 2 receptor agonist 177Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma: Results of the lumed phase 0a study. J Nuclear Med 2020;61. https:\/\/doi.org\/10.2967\/jnumed.119.233031","DOI":"10.2967\/jnumed.119.233031"},{"key":"1491_CR152","doi-asserted-by":"publisher","unstructured":"de Rubio RG, Ransom RF, Malik S, Yule DI, Anantharam A, Smrcka A V. Phosphatidylinositol 4-phosphate is a major source of GPCR-stimulated phosphoinositide production. Sci Signal. 2018;11. https:\/\/doi.org\/10.1126\/scisignal.aan1210","DOI":"10.1126\/scisignal.aan1210"},{"key":"1491_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100926","volume":"14","author":"T Rupp","year":"2021","unstructured":"Rupp T, Pelouin O, Genest L, Legrand C, Froget G, Castagn\u00e9 V. Therapeutic potential of Fingolimod in triple negative breast cancer preclinical models. Transl Oncol. 2021;14:100926 Elsevier.","journal-title":"Transl Oncol"},{"key":"1491_CR154","doi-asserted-by":"publisher","unstructured":"Rurarz BP, Bukowczyk M, Gibka N, Piastowska-Ciesielska AW, Karczmarczyk U, Ula\u0144ski P. Nanostrategies for therapeutic and diagnostic targeting of Gastrin-releasing peptide receptor. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24043455.","DOI":"10.3390\/ijms24043455"},{"key":"1491_CR155","doi-asserted-by":"crossref","unstructured":"Van Der Ryst E. Maraviroc\u2013a CCR5 antagonist for the treatment of HIV-1 infection. Front Immunol. Frontiers Media SA; 2015;6:277.","DOI":"10.3389\/fimmu.2015.00277"},{"key":"1491_CR156","doi-asserted-by":"publisher","unstructured":"Seo J, Lee KJ. Post-translational modifications and their biological functions: proteomic analysis and systematic approaches. J Biochem Mol Biol. 2004. https:\/\/doi.org\/10.5483\/bmbrep.2004.37.1.035.","DOI":"10.5483\/bmbrep.2004.37.1.035"},{"key":"1491_CR157","doi-asserted-by":"publisher","unstructured":"Shen J, Zhang H. Function and structure of Bradykinin receptor 2 for drug discovery. Acta Pharmacol Sin. 2023. https:\/\/doi.org\/10.1038\/s41401-022-00982-8.","DOI":"10.1038\/s41401-022-00982-8"},{"key":"1491_CR158","doi-asserted-by":"publisher","unstructured":"Shen CK, Huang BR, Charoensaensuk V, Yang LY, Tsai CF, Liu YS, et al. Bradykinin B1 receptor affects tumor-associated macrophage activity and glioblastoma progression. Antioxidants Basel. 2023. https:\/\/doi.org\/10.3390\/antiox12081533.","DOI":"10.3390\/antiox12081533"},{"key":"1491_CR159","doi-asserted-by":"crossref","unstructured":"Silva GS, Kim EJ, Barta SK, Chung J. Immune-related adverse events associated with mogamulizumab: A comprehensive review of the literature. Expert Rev Anticancer Ther. Taylor & Francis; 2024;24:819\u201327.","DOI":"10.1080\/14737140.2024.2379914"},{"key":"1491_CR160","doi-asserted-by":"publisher","first-page":"10121","DOI":"10.1038\/s41598-017-09549-8","volume":"7","author":"V Simko","year":"2017","unstructured":"Simko V, Iuliano F, Sevcikova A, Labudova M, Barathova M, Radvak P, et al. Hypoxia induces cancer-associated cAMP\/PKA signalling through HIF-mediated transcriptional control of adenylyl cyclases VI and VII. Sci Rep. 2017;7:10121. https:\/\/doi.org\/10.1038\/s41598-017-09549-8.","journal-title":"Sci Rep"},{"key":"1491_CR161","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/stem.3174","volume":"38","author":"P Singh","year":"2020","unstructured":"Singh P, Mohammad KS, Pelus LM. CXCR4 expression in the bone marrow microenvironment is required for hematopoietic stem and progenitor cell maintenance and early hematopoietic regeneration after myeloablation. Stem Cells Oxford University Press. 2020;38:849\u201359.","journal-title":"Stem Cells Oxford University Press"},{"key":"1491_CR162","doi-asserted-by":"publisher","first-page":"8947","DOI":"10.18632\/oncotarget.2407","volume":"5","author":"EAR Sison","year":"2014","unstructured":"Sison EAR, Magoon D, Li L, Annesley CE, Rau RE, Small D, et al. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition. Oncotarget. 2014;5:8947.","journal-title":"Oncotarget"},{"key":"1491_CR163","doi-asserted-by":"crossref","unstructured":"Siu LL, Papadopoulos K, Alberts SR, Kirchoff-Ross R, Vakkalagadda B, Lang L, et al. A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. J Clin Oncol. Am Soc Clin Oncol 2010;28:2501.","DOI":"10.1200\/jco.2010.28.15_suppl.2501"},{"key":"1491_CR164","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-pharmtox-010919-023340","volume":"61","author":"MJ Smit","year":"2021","unstructured":"Smit MJ, Schlecht-Louf G, Neves M, Van Den Bor J, Penela P, Siderius M, et al. The CXCL12\/CXCR4\/ACKR3 axis in the tumor microenvironment: signaling, crosstalk, and therapeutic targeting. Annu Rev Pharmacol Toxicol Annual Reviews. 2021;61:541\u201363.","journal-title":"Annu Rev Pharmacol Toxicol Annual Reviews"},{"key":"1491_CR165","doi-asserted-by":"publisher","unstructured":"Smith JP, Fonkoua LK, Moody TW. The role of gastrin and CCK receptors in pancreatic cancer and other malignancies. Int J Biol Sci. 2016. https:\/\/doi.org\/10.7150\/ijbs.14952.","DOI":"10.7150\/ijbs.14952"},{"key":"1491_CR166","doi-asserted-by":"publisher","unstructured":"Sriram K, Moyung K, Corriden R, Carter H, Insel PA. GPCRs show widespread differential mRNA expression and frequent mutation and copy number variation in solid tumors. PLoS Biol. 2019;17. https:\/\/doi.org\/10.1371\/journal.pbio.3000434","DOI":"10.1371\/journal.pbio.3000434"},{"key":"1491_CR167","doi-asserted-by":"publisher","unstructured":"Stolwijk JA, Wallner S, Heider J, Kurz B, P\u00fctz L, Michaelis S, et al. GPR4 in the pH-dependent migration of melanoma cells in the tumor microenvironment. Exp Dermatol. 2023. https:\/\/doi.org\/10.1111\/exd.14735.","DOI":"10.1111\/exd.14735"},{"key":"1491_CR168","unstructured":"Strungs EG, Luttrell LM. Arrestins - Pharmacology and therapeutic potential. Handb Exp Pharmacol. 2014;219."},{"key":"1491_CR169","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2165\/11631090-000000000-00000","volume":"72","author":"JM Subramaniam","year":"2012","unstructured":"Subramaniam JM, Whiteside G, McKeage K, Croxtall JC. Mogamulizumab: first global approval. Drugs. 2012;72:1293\u20138 Springer.","journal-title":"Drugs"},{"key":"1491_CR170","doi-asserted-by":"publisher","unstructured":"Sullivan RJ, Tsai KK, Pavlick AC, Buchbinder EI, Agarwala SS, Ribas A, et al. Phase 1b study of Tovorafenib, Plozalizumab or Vedolizumab plus standard-of-care immune checkpoint inhibitors in patients with advanced melanoma. J Cancer. 2025. https:\/\/doi.org\/10.7150\/jca.117878.","DOI":"10.7150\/jca.117878"},{"key":"1491_CR171","doi-asserted-by":"publisher","unstructured":"Sun L, Zhang H, Gao P. Metabolic reprogramming and epigenetic modifications on the path to cancer. Protein Cell. 2022. https:\/\/doi.org\/10.1007\/s13238-021-00846-7.","DOI":"10.1007\/s13238-021-00846-7"},{"key":"1491_CR172","doi-asserted-by":"publisher","unstructured":"Sun Y, Wang H, Qu T, Luo J, An P, Ren F, et al. mTORC2: a multifaceted regulator of autophagy. Cell Commun Signal. 2023. https:\/\/doi.org\/10.1186\/s12964-022-00859-7.","DOI":"10.1186\/s12964-022-00859-7"},{"key":"1491_CR173","doi-asserted-by":"crossref","unstructured":"Tang T, Tang JY, Li D, Reich M, Callahan CA, Fu L, et al. Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Clin Cancer Res Am Assoc Cancer Res 2011;17:3378\u201387.","DOI":"10.1158\/1078-0432.CCR-10-3370"},{"key":"1491_CR174","doi-asserted-by":"crossref","unstructured":"Tiago M, Capparelli C, Erkes DA, Purwin TJ, Heilman SA, Berger AC, et al. Targeting BRD\/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF\/MEK inhibitors in melanoma. Br J Cancer. Nat Publish Group UK London; 2020;122:789\u2013800.","DOI":"10.1038\/s41416-019-0724-y"},{"key":"1491_CR175","doi-asserted-by":"publisher","unstructured":"Uemura H, Ishiguro H, Kubota Y. Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. Int J Urol. 2008. https:\/\/doi.org\/10.1111\/j.1442-2042.2007.01937.x.","DOI":"10.1111\/j.1442-2042.2007.01937.x"},{"key":"1491_CR176","doi-asserted-by":"publisher","unstructured":"Urtatiz O, Van Raamsdonk CD. Gnaq and Gna11 in the Endothelin signaling pathway and melanoma. Front Genet. 2016;7. https:\/\/doi.org\/10.3389\/fgene.2016.00059","DOI":"10.3389\/fgene.2016.00059"},{"key":"1491_CR177","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jpha.2020.01.001","volume":"10","author":"S Usman","year":"2020","unstructured":"Usman S, Khawer M, Rafique S, Naz Z, Saleem K. The current status of anti-GPCR drugs against different cancers. J Pharm Anal Elsevier. 2020;10:517\u201321.","journal-title":"J Pharm Anal Elsevier"},{"key":"1491_CR178","doi-asserted-by":"publisher","unstructured":"Vijayan D, Young A, Teng MWL, Smyth MJ. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer. 2017. https:\/\/doi.org\/10.1038\/nrc.2017.86.","DOI":"10.1038\/nrc.2017.86"},{"key":"1491_CR179","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.critrevonc.2015.11.006","volume":"98","author":"M Wahid","year":"2016","unstructured":"Wahid M, Jawed A, Mandal RK, Dar SA, Khan S, Akhter N, et al. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas. Crit Rev Oncol Hematol Elsevier. 2016;98:235\u201341.","journal-title":"Crit Rev Oncol Hematol Elsevier"},{"key":"1491_CR180","doi-asserted-by":"publisher","first-page":"e29659","DOI":"10.1016\/j.heliyon.2024.e29659","volume":"10","author":"Y Wang","year":"2024","unstructured":"Wang Y, Jin B, Wu X, Xing J, Zhang B, Chen X, et al. Exploration of prognostic and treatment markers in hepatocellular carcinoma via GPCR-related genes analysis. Heliyon. 2024;10:e29659. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e29659.","journal-title":"Heliyon"},{"key":"1491_CR181","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2967\/jnumed.123.265670","volume":"64","author":"WA Weber","year":"2023","unstructured":"Weber WA, Barthel H, Bengel F, Eiber M, Herrmann K, Sch\u00e4fers M. What is theranostics. J Nucl Med. 2023;64:669\u201370.","journal-title":"J Nucl Med"},{"key":"1491_CR182","doi-asserted-by":"publisher","unstructured":"de Wiele C, Boersma H, Dierckx R, De Spiegeleer B, Waarde A, Elsinga P. Growth factor\/Peptide receptor imaging for the development of targeted therapy in oncology. Curr Pharm Des. 2008;14. https:\/\/doi.org\/10.2174\/138161208786549434","DOI":"10.2174\/138161208786549434"},{"key":"1491_CR183","doi-asserted-by":"publisher","unstructured":"Wiley SZ, Sriram K, Liang W, Chang SE, French R, McCann T, et al. GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells. FASEB J. 2018. https:\/\/doi.org\/10.1096\/fj.201700834R.","DOI":"10.1096\/fj.201700834R"},{"key":"1491_CR184","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3390\/pharmaceutics15030958","volume":"15","author":"A Wu","year":"2023","unstructured":"Wu A, Turner KA, Woolfson A, Jiang X. The Hedgehog pathway as a therapeutic target in chronic myeloid leukemia. Pharmaceutics. 2023;15:958 MDPI.","journal-title":"Pharmaceutics"},{"key":"1491_CR185","doi-asserted-by":"publisher","unstructured":"Wu V, Yeerna H, Nohata N, Chiou J, Harismendy O, Raimondi F, et al. Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy. J Biol Chem 2019;294. https:\/\/doi.org\/10.1074\/jbc.REV119.005601","DOI":"10.1074\/jbc.REV119.005601"},{"key":"1491_CR186","doi-asserted-by":"publisher","unstructured":"Xia S, Ma J, Bai X, Zhang H, Cheng S, Zhang M, et al. Prostaglandin e2 promotes the cell growth and invasive ability of hepatocellular carcinoma cells by upregulating c-Myc expression via EP4 receptor and the PKA signaling pathway. Oncol Rep. 2014;32. https:\/\/doi.org\/10.3892\/or.2014.3393","DOI":"10.3892\/or.2014.3393"},{"key":"1491_CR187","doi-asserted-by":"publisher","first-page":"108892","DOI":"10.4251\/wjgo.v17.i9.108892","volume":"17","author":"W Xie","year":"2025","unstructured":"Xie W, Li X-J, Zhong Y-S, Fang J, Qi H, Yang M, et al. Ginsenoside F4 inhibits colorectal cancer progression by boosting dendritic cell maturation and remodeling the tumor microenvironment. World J Gastrointest Oncol. 2025;17:108892.","journal-title":"World J Gastrointest Oncol"},{"key":"1491_CR188","doi-asserted-by":"publisher","unstructured":"Xu S, Zhou W, Ge J, Zhang Z. Prostaglandin E2 receptor EP4 is involved in the cell growth and invasion of prostate cancer via the cAMP-PKA\/PI3K-Akt signaling pathway. Mol Med Rep. 2018. https:\/\/doi.org\/10.3892\/mmr.2018.8415.","DOI":"10.3892\/mmr.2018.8415"},{"key":"1491_CR189","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.1038\/s44319-024-00292-6","volume":"25","author":"C Xu","year":"2024","unstructured":"Xu C, Wang Y, Ni C, Xu M, Yin C, He Q, et al. Histone modifications and Sp1 promote GPR160 expression in bone cancer pain within rodent models. EMBO Rep. 2024;25:5429\u201355. https:\/\/doi.org\/10.1038\/s44319-024-00292-6.","journal-title":"EMBO Rep"},{"key":"1491_CR190","doi-asserted-by":"crossref","unstructured":"Yauch RL, Dijkgraaf GJP, Alicke B, Januario T, Ahn CP, Holcomb T, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (1979). American Association for the Advancement of Science; 2009;326:572\u20134.","DOI":"10.1126\/science.1179386"},{"key":"1491_CR191","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/pros.22544","volume":"73","author":"H Yu","year":"2013","unstructured":"Yu H, Lin T, Tang C. Bradykinin enhances cell migration in human prostate cancer cells through B2 receptor\/PKC\u03b4\/c\u2010Src dependent signaling pathway. Prostate. 2013;73:89\u2013100. https:\/\/doi.org\/10.1002\/pros.22544.","journal-title":"Prostate"},{"key":"1491_CR192","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.4155\/fmc-2018-0200","volume":"10","author":"H Zhang","year":"2018","unstructured":"Zhang H, Sun Z, Liu Z, Song C. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity. Future Med Chem Taylor & Francis. 2018;10:2855\u201375.","journal-title":"Future Med Chem Taylor & Francis"},{"key":"1491_CR193","doi-asserted-by":"publisher","unstructured":"Zhang H, Kong Q, Wang J, Jiang Y, Hua H. Complex roles of cAMP\u2013PKA\u2013CREB signaling in cancer. Exp Hematol Oncol. 2020. https:\/\/doi.org\/10.1186\/s40164-020-00191-1.","DOI":"10.1186\/s40164-020-00191-1"},{"key":"1491_CR194","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.2174\/0929867327666200610174453","volume":"28","author":"S Zhang","year":"2021","unstructured":"Zhang S, Chen Y, Tian C, He Y, Tian Z, Wan Y, et al. Dual-target inhibitors based on BRD4: Novel therapeutic approaches for cancer. Curr Med Chem Bentham Sci Publishers. 2021;28:1775\u201395.","journal-title":"Curr Med Chem Bentham Science Publishers"},{"key":"1491_CR195","doi-asserted-by":"publisher","unstructured":"Zhang B, Li S, Shui W. Post-translational modifications of G protein-coupled receptors revealed by proteomics and structural biology. Front Chem. 2022. https:\/\/doi.org\/10.3389\/fchem.2022.843502.","DOI":"10.3389\/fchem.2022.843502"},{"key":"1491_CR196","doi-asserted-by":"publisher","unstructured":"Zhang H, Liu Y, Liu J, Chen J, Wang J, Hua H, et al. cAMP-PKA\/EPAC signaling and cancer: the interplay in tumor microenvironment. J Hematol Oncol. 2024. https:\/\/doi.org\/10.1186\/s13045-024-01524-x.","DOI":"10.1186\/s13045-024-01524-x"},{"key":"1491_CR197","doi-asserted-by":"publisher","unstructured":"Zhang M, Zhao J, Dong H, Xue W, Xing J, Liu T, et al. DNA Methylation-Specific Analysis of G Protein-Coupled Receptor-Related Genes in Pan-Cancer. Genes (Basel). 2022;13. https:\/\/doi.org\/10.3390\/genes13071213","DOI":"10.3390\/genes13071213"},{"key":"1491_CR198","doi-asserted-by":"publisher","unstructured":"Zhao M, Wang T, Liu Q, Cummins S. Copy number alteration of neuropeptides and receptors in multiple cancers. Sci Rep. 2017;7. https:\/\/doi.org\/10.1038\/s41598-017-04832-0","DOI":"10.1038\/s41598-017-04832-0"},{"key":"1491_CR199","doi-asserted-by":"publisher","unstructured":"Zhu H, Wang G, Qian J. Transcription factors as readers and effectors of DNA methylation. Nat Rev Genet. 2016;17. https:\/\/doi.org\/10.1038\/nrg.2016.83","DOI":"10.1038\/nrg.2016.83"},{"key":"1491_CR200","doi-asserted-by":"crossref","unstructured":"Zhuang Y, Zhao X, Yuan B, Zeng Z, Chen Y. Blocking the CCL5\u2013CCR5 axis using maraviroc promotes M1 polarization of macrophages cocultured with irradiated hepatoma cells. J Hepatocell Carcinoma. Taylor & Francis; 2021;599\u2013611.","DOI":"10.2147\/JHC.S300165"},{"key":"1491_CR201","doi-asserted-by":"publisher","unstructured":"Zippin JH, Farrell J, Huron D, Kamenetsky M, Hess KC, Fischman DA, et al. Bicarbonate-responsive \u201csoluble\u201d adenylyl cyclase defines a nuclear cAMP microdomain. J Cell Biol. 2004;164. https:\/\/doi.org\/10.1083\/jcb.200311119","DOI":"10.1083\/jcb.200311119"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-026-01491-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01491-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01491-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:12:07Z","timestamp":1782727927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10020-026-01491-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":201,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1491"],"URL":"https:\/\/doi.org\/10.1186\/s10020-026-01491-8","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}